Literature DB >> 9713567

Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome.

G Grugni1, G Guzzaloni, D Moro, D Bettio, C De Medici, F Morabito.   

Abstract

OBJECTIVE: It is unclear whether the blunted GH secretion in Prader-Willi Syndrome (PWS) is a true deficiency, or merely secondary to obesity. We have investigated the role of obesity in the blunted GH secretion in PWS.
DESIGN: We studied the GH response to a combined administration of GHRH (1 microgram/kg i.v. at 0 min) and pyridostigmine (PD) (60 and 120 mg by mouth for children and adults, respectively, at time -60 min), as well as the baseline IGF-I levels, in a group of patients with PWS. Two different control groups were studied with GHRH + PD using the same doses and methods as above: prepubertal and pubertal obese subjects, and prepubertal short normal children. Moreover, in 14 patients with PWS and in the group of short normals the GH response to at least two stimulation tests (insulin tolerance test, clonidine, L-dopa, arginine) had been previously determined. PATIENTS: Twenty-two PWS patients (10 males and 12 females), 21 with essential obesity (11 males and 10 females), and eight short normal children (4 males and 4 females) were studied after obtaining informed consent. MEASUREMENTS: Blood samples were taken at -60, -30 and 0 min and then 15, 30, 45, 60, 90 and 120 min after GHRH administration. Serum GH was measured in duplicate by IRMA, and IGF-I by RIA after acid ethanol extraction. Statistical analysis was performed by t-test for unpaired data, and analysis of variance for parametric or nonparametric data, where appropriate.
RESULTS: The GH response to GHRH + PD was significantly lower in PWS patients (AUC: mean +/- SE: 599 +/- 99 micrograms/l/h) if compared with either short normal children (3294 +/- 461 micrograms/l/h: P < 0.0001) or obese subjects (1445 +/- 210 micrograms/l/h: P < 0.005). Low IGF-I concentrations were found in all PWS patients, so that PWS group had mean IGF-I levels significantly lower than the other groups.
CONCLUSIONS: Our results showed that subjects with PWS had a reduced GH responsiveness to GHRH + PD associated with subnormal IGF-I levels. These findings suggested that short stature in PWS may be at least partially correlated to the presence of GH deficiency, and that impaired GH secretion is not secondary to obesity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713567     DOI: 10.1046/j.1365-2265.1998.00435.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.

Authors:  A Corrias; J Bellone; L Beccaria; L Bosio; G Trifirò; C Livieri; L Ragusa; A Salvatoni; M Andreo; P Ciampalini; G Tonini; A Crinò
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

2.  Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.

Authors:  G Grugni; G Guzzaloni; F Morabito
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

3.  Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.

Authors:  L A Gondoni; L Vismara; P Marzullo; R Vettor; A Liuzzi; G Grugni
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

Review 4.  Prader Willi Syndrome: Genetics, Metabolomics, Hormonal Function, and New Approaches to Therapy.

Authors:  Krystal A Irizarry; Mark Miller; Michael Freemark; Andrea M Haqq
Journal:  Adv Pediatr       Date:  2016-08

5.  Changes in body composition, blood lipid profile, and growth factor hormone in a patient with Prader-willi syndrome during 24 weeks of complex exercise: a single case study.

Authors:  Hee Joung Joung; In Soo Lim
Journal:  J Exerc Nutrition Biochem       Date:  2018-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.